FY2025 · period end Dec '25 · from the 10-K filed Mar 13, 2026
| Metric | FY25Dec '25 | FY24Dec '24 | FY23Dec '23 | FY22Dec '22 | FY21Dec '21 |
|---|---|---|---|---|---|
| Revenue | $0.92B | $0.97B | $1.22B | $1.34B | $1.21B |
| Gross Profit | $0.03B | $0.01B | $0.02B | negative: -$0.03B | $0.07B |
| Operating Income | $0.01B | negative: -$0.05B | negative: -$0.02B | negative: -$0.06B | $0.04B |
| Net Income | $0.00B | negative: -$0.00B | negative: -$0.03B | negative: -$0.04B | $0.04B |
| EPS (Diluted) | $0.16 | negative: -$0.79 | negative: -$0.37 | negative: -$0.60 | $0.61 |
| Metric | FY25Dec '25 | FY24Dec '24 | FY23Dec '23 | FY22Dec '22 | FY21Dec '21 |
|---|---|---|---|---|---|
| Total Assets | $0.39B | $0.40B | $0.45B | $0.48B | $0.48B |
| Total Liabilities | $0.14B | $0.18B | $0.17B | $0.17B | $0.14B |
| Stockholders' Equity | $0.25B | $0.23B | $0.28B | $0.31B | $0.35B |
| Cash & Equivalents | $0.02B | $0.04B | $0.03B | $0.04B | $0.05B |
| Total Debt | — | — | — | — | — |
| Metric | FY25Dec '25 | FY24Dec '24 | FY23Dec '23 | FY22Dec '22 | FY21Dec '21 |
|---|---|---|---|---|---|
| Operating Cash Flow | $0.01B | negative: -$0.00B | $0.02B | $0.01B | $0.03B |
| Capital Expenditures | $0.00B | $0.01B | $0.03B | $0.04B | $0.02B |
| Free Cash Flow | $0.01B | negative: -$0.01B | negative: -$0.01B | negative: -$0.03B | $0.01B |
| Metric | FY25Dec '25 | FY24Dec '24 | FY23Dec '23 | FY22Dec '22 | FY21Dec '21 |
|---|---|---|---|---|---|
| Gross Margin | 3.8% | 1.0% | 1.3% | negative: -2.1% | 5.6% |
| Operating Margin | 0.0% | negative: -0.1% | negative: -0.0% | negative: -0.0% | 3.3% |
| Net Margin | 0.0% | negative: -0.0% | negative: -0.0% | negative: -0.0% | 3.7% |
| Return on Equity | 0.0% | negative: -0.0% | negative: -10.0% | negative: -13.1% | 12.8% |
| Return on Assets | 0.0% | negative: -0.0% | negative: -6.3% | negative: -8.9% | 9.1% |
| Debt / Equity | 0.32× | 0.41× | 0.29× | 0.22× | — |
Showing the most recent 5 annual periods. Get 15 years of history on the Pro plan, or unlimited history back to 1993 plus the smart-money dataset and webhooks on Institutional.
| Form | Accession ID | Report Date | Filing Date | Accepted At | Source |
|---|---|---|---|---|---|
| 10-Q | 0001213900-26-086336 | Jun 30, 2026 | Aug 7, 2026 | Aug 7, 2026 00:59 UTC | EDGAR |
| 8-K | 0001213900-26-086750 | Aug 5, 2026 | Aug 7, 2026 | Aug 7, 2026 20:44 UTC | EDGAR |
| 8-K | 0001213900-26-085686 | Aug 5, 2026 | Aug 5, 2026 | Aug 5, 2026 20:18 UTC | EDGAR |
| 8-K | 0001213900-26-071111 | Jun 23, 2026 | Jun 23, 2026 | Jun 23, 2026 20:18 UTC | EDGAR |
| 10-Q | 0001213900-26-053870 | Mar 31, 2026 | May 8, 2026 | May 8, 2026 20:06 UTC | EDGAR |
| 8-K | 0001213900-26-052830 | May 6, 2026 | May 6, 2026 | May 6, 2026 20:25 UTC | EDGAR |
| 10-K | 0001213900-26-027687 | Dec 31, 2025 | Mar 13, 2026 | Mar 13, 2026 20:16 UTC | EDGAR |
| 8-K | 0001213900-26-023650 | Mar 4, 2026 | Mar 4, 2026 | Mar 4, 2026 21:11 UTC | EDGAR |
Direct links to SEC EDGAR. ALTO has additional filings available on the SEC site.
6 numbers Alto Ingredients, Inc. later changed — same XBRL tag, both filings linked.
Net Cash Provided by (Used in) Operating Activities·Q2 2021
Major restatementwas$763K
Revised up in a 10-Q. Any P/OCF built on the original was 81.0% too high.
Net Income (Loss) Attributable to Parent·FY 2024
Major restatementwas-$59M
Revised up.
Net Income (Loss) Attributable to Parent·FY 2025
Major restatementwas$13.3M
Revised down.
Gross Profit·Q1 2016
Major restatementwas$1.1M
Revised up in a 10-K.
Net Cash Provided by (Used in) Operating Activities·FY 2019
Major restatementwas-$23.4M
Revised down in a 10-K.
Long-term Debt and Lease Obligation·As of Dec 31, 2013
Major restatementwas$127.9M
Revised down in a 10-K.
ALTO is not the only one.
See every restatement we've found across the market — or get an alert the next time ALTO revises a number.
Restatements are detected by comparing every vintage of a fact across all of Alto Ingredients, Inc.'s filings back to 1993. A revision is not by itself a sign of wrongdoing — companies re-file for many legitimate reasons. This list is not exhaustive: it shows ALTO's most significant revisions, and a figure absent from it has not been certified as unrevised.
Who is buying and selling Alto Ingredients, Inc. — insider transactions from Forms 3/4/5/144 and institutional ownership from 13F, 13D, and 13G filings, point-in-time stamped like every other fact in the library. Traders read it as a positioning signal; risk desks read it as concentration.
No published research on ALTO yet.
Reports appear here as analysts publish research on this company — built with Valuein's agentic workflows, every figure pinned to its SEC filing. Be the first: run equity_research_brief on ALTO and publish the result to your public profile.
Ask about Alto Ingredients, Inc.
Continue in Workspace — cited answers on ALTO, a thesis you can score, or a signal on the next filing.
Open in WorkspaceGet 15 years of data
Quarterly and annual financials back to 2011 on Pro (1993 on Institutional). Point-in-time accurate with zero survivorship bias.
View plansQuery via Python SDK
Pull data into DuckDB with 3 lines of Python. Works in Jupyter notebooks, scripts, and CI pipelines.
SDK docsConnect via MCP Server
Wire Claude, Cursor, or Codex directly to live SEC data with a single Bearer token. No scraping, no glue code.
MCP docs